ERBB2 and neoplasm: We demonstrate similar immune activation in ER+/HER2+ tumours, including upregulation of immune-checkpoint inhibitors related signatures such as PD1, PDL2,TIGIT or IDO1 and other immune-related genes such as TGF-beta or macrophages particularly in tumours showing higher sensitivity to AI as indicated by Ki67 reductions.